FDA Approves New Convenia RTU for Dogs
The FDA has authorized Zoetis Inc. to market a new injectable treatment for specific bacterial skin infections in dogs.
Updated on Oct. 28, 2026 in Veterinary Medicine
The FDA has granted approval for Convenia RTU for Dogs, an injectable treatment designed to combat bacterial skin infections. Manufactured by Kalamazoo-based Zoetis Inc., the medication is specifically formulated for canine use.
Why it matters
This approval expands the available treatment options for veterinarians managing skin infections caused by Staphylococcus pseudintermedius and Streptococcus canis in dogs. The move follows the legacy of the original cefovecin injectable first approved for pets in 2008.
The new injectable contains cefovecin sodium at a concentration of 160 mg/mL. Veterinarians must shake each 10-mL multidose vial for 60 seconds and use a 20-gauge needle for proper administration.
The players
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs.
Zoetis Inc.
Headquartered in Kalamazoo, Michigan, this company is a global leader in the animal health industry, focusing on the discovery and development of medicines for livestock and companion animals.
The details
This treatment is intended for use in dogs only to address specific bacterial skin infections. The formulation includes active ingredients alongside benzyl benzoate and propylene glycol.
Timeline
The original cefovecin product for dogs and cats was first approved in 2008.
The FDA approved the new Convenia RTU for Dogs on October 28, 2026.
Culture Shift
This development continues the evolution of veterinary dermatology treatments following the 2008 approval of the original cefovecin injectable. It reflects a broader industry trend toward refining long-acting injectable medications for domestic pets.
Dog owners may see this new treatment option offered by their local veterinarians for managing specific bacterial skin infections. Owners should consult their vet to determine if this injectable is an appropriate therapy compared to existing treatment routines.
The takeaway
The introduction of this new formulation offers clinicians updated tools to manage canine skin health. Pet owners should remain aware that proper administration requires specific technical steps by trained professionals.
Further reading
For more on evolving standards in animal healthcare, visit the Veterinary Medicine section.
Source note: This article includes information reported by Veterinary Practice News.
